EnGeneIC granted FDA "Fast-Track" Designation for Novel Armed Nanocell Drug Conjugate (ANDC) Pancreatic Cancer Therapeutic, Business News
EnGeneIC granted FDA “Fast-Track” Designation for Novel Armed Nanocell Drug Conjugate (ANDC) Pancreatic Cancer Therapeutic GlobeNewswire December 08, 2023 SYDNEY, Australia and NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- EnGeneIC, an innovative biopharmaceutical company leading the field of armed antibody therapeutics for oncology, has achieved a significant milestone with the granting...
Source: asiaone.com